磷酸奥司他韦颗粒治疗甲型或乙型流感病毒引起小儿上呼吸道感染患儿的疗效

Efficacy of Oseltamivir Phosphate Granules in the Treatment of Children with Upper Respiratory Tract Infection Caused by Influenza A or B virus

目的探讨磷酸奥司他韦颗粒治疗甲型或乙型流感病毒引起的小儿上呼吸道感染患儿的疗效。方法选取2018年7月至2019年7月湛江市妇幼保健院门诊收治的上呼吸道感染患儿74例作为研究对象,采用随机数字表法分为对照组与观察组,每组37例。对照组患儿给予四季抗病毒合剂治疗,观察组患儿在对照组基础上服用磷酸奥司他韦颗粒治疗,比较两组患儿临床症状缓解时间、临床疗效以及不良反应发生情况。结果观察组疲劳、高热及鼻塞缓解时间均明显短于对照组,差异有统计学意义(P<0.05);观察组治疗有效率为91.89%,不良反应发生率为10.81%,对照组治疗有效率为56.76%,不良反应发生率为29.73%,观察组与对照组比较临床疗效增加,不良反应发生率降低,差异有统计学意义(P<0.05)。结论在小儿上呼吸道感染治疗中,采用磷酸奥司他韦颗粒进行治疗,可快速缓解患儿临床症状,具有更好的临床疗效以及较少不良反应发生,有利于临床治疗。

Objective To explore the efficacy of oseltamivir phosphate granules in the treatment of children with upper respiratory tract infection caused by influenza A or B virus. Methods From July 2018 to July 2019, 74 children with upper respiratory tract infection admitted to the Outpatient Department of Zhanjiang Maternal and Child Health Care Hospital were selected as the study objects, and randomly divided into control group and observation group with 37 cases in each group. The children in the control group were given four seasons antiviral mixture treatment. The children in the observation group were treated with oseltamivir phosphate granules on the basis of the control group. The clinical symptom relief time, clinical efficacy and adverse reactions were compared between the 2 groups. Results The time of fatigue, high fever and nasal obstruction relief in the observation group were significantly shorter than that in the control group(P<0.05);the effective rate of treatment in the observation group was 91.89%, the incidence of adverse reactions was 10.81%, the effective rate of treatment in the control group was 56.76%, and the incidence of adverse reactions was 29.73%. Compared with the control group, the clinical efficacy of the observation group increased, and the incidence of adverse reactions decreased(P<0.05). Conclusion In the treatment of child patients with upper respiratory tract infection, oseltamivir phosphate granules can rapidly relieve the clinical symptoms of children, with better clinical efficacy and less adverse reactions, which is conducive to clinical treatment.